TuBerculosis Vaccine Initiative (TBVI) and Aeras announce vaccines MOU

The TuBerculosis Vaccine Initiative (TBVI) and Aeras announced a new memorandum of understanding “to enhance and strengthen collaborative efforts to advance the world’s most promising TB vaccine candidates.” Aeras is “a nonprofit global TB vaccine biotech based in the US and South Africa” and TBVI is “a pan-European TB vaccine research foundation based in the Netherlands.” The relationship “will address significant scientific opportunities and challenges described in Tuberculosis Vaccines: A Strategic Blueprint for the Next Decade” – a unified global strategy published last month in the journal Tuberculosis which provides a comprehensive approach for developing and introducing safe and effective TB vaccines over the next decade.” Jim Connolly, President and CEO of Aeras, said, “Without new TB vaccines, we cannot end this epidemic. TB vaccine development is particularly complex and costly, and to achieve our mission it is critical to bring together the best and brightest minds in the field. Aeras is looking forward to expanding our collaboration with TBVI, whose role has been pivotal in fueling the quality of research in Europe and the development of promising new vaccine candidates.” Dr. Jelle Thole, Director of TBVI, said, “Aeras has deep experience with preclinical and clinical evaluation of TB vaccine candidates and expertise in identifying promising vaccines. This provides important added value to our know-how. Together we are able to develop vaccines as cost-effectively and efficiently as possible, moving seamlessly from early laboratory research through clinical development to licensure, to deliver vaccines to communities that need their protection.”